Although the five-year survival of childhood acute lymphoblastic leukaemia (ALL) exceeds 80%, a group of patients presents poor prognosis due to early relapse (van den Berg *et al*, [@b2]). To date, treatment strategies have been defined by cytogenetically-based subtype categorization. However, ALL patients without chromosomal translocations associated with poor prognosis lack diagnostic markers that would allow specific therapies to be developed. DNA methylation alteration is a frequent event in cancer and is potentially very useful in the diagnosis, prognosis and prediction of drug response ([@b8]). Hence, we attempted to characterize childhood B-ALLs without Philadelphia (*BCR-ABL1*) and *MLL* translocations on the basis of the DNA methylation profile of more than 450 000 CpG sites with the aim of providing a means to improve the accuracy of prognosis and treatment strategies. All the obtained DNA methylation data have been deposited in the Gene Expression Omnibus (GEO) database in the following link: <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bfsbfcigsakcuty&acc=GSE39141>

We derived genome-wide DNA methylation profiles of 29 childhood B-ALL patients and four normal B-cell samples (NBC) using the Infinium 450 K DNA methylation Bead assay (450 K) ([@b3]). Twenty-five patient samples were obtained at the time of diagnosis (including 10 cytogenetically normal, eight hyperdiploid, five pseudodiploid and two unclassified samples) and four samples at disease relapse ([Table 1](#tbl1){ref-type="table"}). Profiling varying 11 112 CpG sites (SD\>0·25) within all samples analysed clearly distinguished healthy B-cell specimens from B-ALL patient samples ([Fig 1](#fig01){ref-type="fig"}A).

![Genome-wide DNA methylation profile of B-cell ALL patients. (A) Unsupervised hierarchical clustering of four normal B-cell donors (yellow) and 29 ALL patients (orange) using CpGs with standard deviation\>0.25. The cytogenetic subtypes and disease recurrence is indicated. (B) Comparison of variability at 436,346 CpG sites across normal B-cell (NBC) and B-ALL (ALL) samples. (C) Variability of methylation levels across CpG sites within CpG islands (CGI) and outside CpG islands (non-CGI). (D) Box plot displaying the distribution of β-values of total, promoter, islands in promoters and shores in promoters associated with differentially methylated CpG sites of B-ALL *versus* NBC samples. Significance is indicated by an asterisk. (E) Kaplan-Meier curve showing time to relapse of patients in B-ALL group 1 (ALL-1) and group 2 (ALL-2). Biopsies from four of the five patients that recurred were taken at the time of relapse. (F) Variability of DNA methylation levels in differentially methylated CpG sites in groups ALL-1 and ALL-2. (G) Hierarchical cluster of 20 661 differentially methylated CpG sites between B-ALL groups ALL-1 and ALL-2. (H) Genomic distribution of the 17 182 hypomethylated and 3 479 hypermethylated CpGs sites in ALL-2 compared with group ALL-1 with respect to functional genomic distribution (promoter, gene body, 3′UTR and intergenic) and CpG content (CpG island, shore, shelf and open sea).](bjh0160-0406-f1){#fig01}
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Clinical characteristics of the B-ALL samples

  Number of patients                             29
  ---------------------------------------------- -----------------------------------------
  Age, years; median (range)                     4·0 (1·2--17)
   \<1 year (%)                                  0 (0)
   1-10 years (%)                                21 (72)
   \>10 years (%)                                8 (28)
  Sex                                            
   Male (%)                                      15 (52)
   Female (%)                                    14 (48)
  White blood cell count                         
   \<50 x 10^9^/l (%)                            23 (79)
   \>50 x 10^9^/l (%)                            4 (14)
   Unknown (%)                                   2 (7)
  Cytogenetic abnormality                        
   High Hyperdiploidy (51--81 chromosomes) (%)   8 (28)
   Pseudodiploidy (%)                            6 (21)
   Normal (%)                                    12 (41)
   No result (%)                                 3 (10)
  Treatment protocol                             
   SHOP/LAL 99 (%)                               14 (48)
   SHOP/LAL 2005 (%)                             11 (38)
   Not specified (%)                             4 (14)
   Median follow-up (years)                      6·5
  Relapse                                        
   Yes (%)                                       5 (17)[\*](#tf1-1){ref-type="table-fn"}
   No (%)                                        24 (83)

Four out of five samples taken at relapse.

SHOP/LAL, Sociedad Española de Hematología Pediátrica /Leucemia Aguda Linfoblástica.

Overall, B-ALL samples had a significantly greater variance in DNA methylation level than NBC samples (Wilcoxon test, *P* \< 0·01) with 11% and 56% showing a standard deviation greater than 0·05% in healthy and ALL samples, respectively ([Fig 1](#fig01){ref-type="fig"}B). We further noted that most of the variation in ALL samples was a loss of DNA methylation located outside of the CpG rich (CpG island; CGI) context (62%, SD\>0·05). However, the highest variance (SD≥0·25) was DNA hypermethylation found within the CGI context ([Fig 1](#fig01){ref-type="fig"}C, Fig S1), consistent with previous results obtained with lower coverage platforms ([@b7]).

To obtain closer insight into the nature of variant sites, we determined differentially methylated CpG sites (dmCpGs) between healthy and cancer specimens (Table S1). We identified 3,414 dmCpGs, 88·2% (3,014) and 11·8% (400) of which respectively lost and gained DNA methylation in cancer samples ([Fig 1](#fig01){ref-type="fig"}D; Fig S2). Despite the predominantly hypomethylated dmCpGs, CGIs in gene promoters significantly gained DNA methylation at dmCpGs (Wilcoxon test; *P* \< 0·01). Interestingly, the CGIs flanking CpG-poor regions (CpG island shores) were hypomethylated in ALL samples (Wilcoxon test; *P* \< 0·01), consistent with previous studies identifying both regions as being highly variable in different cancer types, including leukaemia ([@b7]; [@b5]).

Analysing variant CpG sites in an unsupervised manner, we identified two clearly distinct DNA methylome profiles in B-ALL patients ([Fig 1](#fig01){ref-type="fig"}A). While 14 samples (ALL-1) displayed highly aberrant methylation levels compared with the control, 15 samples (ALL-2) showed close similarities to healthy B-cells. Most strikingly, the five with disease-relapse-associated samples were all present in ALL-2 (5/15; X^2^ test, *P* \< 0·01), presenting a signature with a significant association between DNA methylation and disease-free survival (log-rank Mantel-Cox test, *P* \< 0·01; [Fig 1](#fig01){ref-type="fig"}E) and suggesting a possible application in future therapy strategies by taking into account epigenetically defined groups as previously suggested ([@b7]).

Considering the presence of distinct DNA methylation subtypes in childhood B-ALLs and their potential application in clinical practice, we extracted a DNA methylation profile represented by 20 661 dmCpGs that distinguished the two groups (Table S2). In total, we detected 17 182 hypo- and 3 479 hypermethylated CpG sites in ALL-2 compared with ALL-1, respectively; differing in variance and associated with unique genomic features ([Fig 1](#fig01){ref-type="fig"}F-H). Confirming the signature in a 10-fold cross-validation model (area under the curve: 89·5), we concluded that the signature reliably detected both B-ALL subtypes and is thus an important tool for future disease diagnosis.

In order to determine the affected biological and disease-associated pathways, we analysed the gene ontology (GO) of hyper- and hypomethylated CpG sites located in gene promoters. We noticed an enrichment (GO, level 5) of genes related to lymphocyte (including B-cell) differentiation in 672 gene promoters presenting higher methylation level in ALL-2 (false discovery rate \[FDR\]\<0·05, Table S3). These genes include *FOXP1*, *TCF3*, *BLNK*, *CD79A*, *RAG1* and *RAG2*, also associated with chromosomal translocations in ALLs and mutation in B-cell maturation-defective syndromes. We suggest that defects in the B-cell differentiation process display a unique property of samples present in ALL-2.

The 2 608 genes associated with promoters showing less methylation in ALL-2 were highly enriched in developmental genes (FDR\<0·05), including 97 *HOX* genes (Table S4). From the epigenetic point of view, developmental genes are associated with the Polycomb (Pc) complex and are marked by the histone modification H3K27me3. Interestingly, 43% (281 out of 654) of Polycomb target genes (PcTG) displayed lower methylation in ALL-2 gene promoters and were significantly enriched compared with promoters gaining methylation (X^2^ test, *P* \< 0·01) ([@b6]). Accordingly, we found 24% (2181 out of 9052) of hypomethylated CpG sites associated with and significantly enriched in the Polycomb histone mark H3K27me3 (X^2^ test, *P* \< 0·01, Fig S3) (Ernst *et al*, 2011). Taken together, the GO and PcTG analyses suggest that hypomethylation of genes involved in developmental processes are a unique feature of patient samples present in ALL-2. Hypermethylation of PcTG ([@b10]) has been previously identified as good prognostic markers in acute myeloid leukaemia patients, supporting the predictive potential of DNA methylation signatures in leukaemia. In addition, overexpression of *HOX* genes has been related to oncogenic transformation ([@b1]) and an increase in stem cell self-renewal ([@b9]) in leukaemia cells.

Overall, genome-wide screening of DNA methylation in normal B-cells and primary B-ALL samples revealed distinct profiles, but most importantly defined two previously unknown B-ALL subtypes. Furthermore, we hypothesize that epigenetic changes mediate an undifferentiated stem cell-like phenotype of a newly identified B-ALL subtype that is possibly associated with drug resistance, resulting in disease relapse and presenting a signature of potential clinical use in the future.
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**Fig S1**DNA methylation level in different genomic features.

**Fig S2**Differentially methylated CpG site (dmCpG) between B-cell (NBC) and B-ALL (ALL) samples.

**Fig S3**Relative number of hyper- and hypomethylated differentially methylated sites between ALL-1 and ALL-2 considering their overlap with loci occupied by different histone marks, H2A.Z and CTCF.

**Table S1**3,414 differentially methylated CpG sites comparing healthy B-cells and B-ALL samples.

**Table S2**20,661 differentially methylated CpG sites comparing B-cell group ALL-1 and ALL-2.

**Table S3**Gene ontology analysis of hypomethylated gene promoters in group ALL-2.
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